Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
DISCUSSION This trial included 20 EGFR T790M-positive advanced NSCLC patients, all of whom had progressed after previous treatment of first-generation EGFR TKIs. Therefore, this phase 1 trial was also a preliminary evaluation of the anti-resistance effects of SH-1028, a novel third-generation EGFR-TKI, to define the value of further study and lay a foundation for the phase 2 trial.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
